Cisen Pharmaceutical Co., Ltd. (603367.SS)
CNY 14.05
(0.0%)
CNY 14.05
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.46 Billion | 4.06 Billion | 3.78 Billion | 3.67 Billion | 4.11 Billion | 3.8 Billion |
| Cost of Revenue | 1.91 Billion | 1.78 Billion | 1.68 Billion | 1.57 Billion | 1.75 Billion | 1.62 Billion |
| Gross Profit | 2.54 Billion | 2.27 Billion | 2.09 Billion | 2.1 Billion | 2.36 Billion | 2.18 Billion |
| Operating Expenses | 2.01 Billion | 1.91 Billion | 1.81 Billion | 1.68 Billion | 1.82 Billion | 1.61 Billion |
| Selling, General and Administrative Expenses | 1.43 Billion | 1.39 Billion | 1.31 Billion | 1.23 Billion | 1.36 Billion | 1.14 Billion |
| Research and Development Expenses | 333.35 Million | 335.16 Million | 334.34 Million | 309.58 Million | 310.56 Million | 325.98 Million |
| Other Expenses | 223.12 Million | 192.62 Million | 160.52 Million | 133.05 Million | 146.37 Million | 2.36 Million |
| Cost and Expenses | 3.86 Billion | 3.7 Billion | 3.49 Billion | 3.25 Billion | 3.57 Billion | 3.23 Billion |
| Operating Income | 592.57 Million | 364.58 Million | 334.42 Million | 484.67 Million | 582.71 Million | 565.61 Million |
| Interest Expense | 8.46 Million | 4.29 Million | 6.09 Million | 9.8 Million | 264.02 Thousand | - |
| Income Tax Expense | 70.43 Million | 13.8 Million | 2.23 Million | 47.15 Million | 67.31 Million | 64.92 Million |
| Earnings before Tax | 595.85 Million | 366.19 Million | 336.13 Million | 484.51 Million | 582.11 Million | 567.97 Million |
| Net Income | 521.33 Million | 349.95 Million | 334.14 Million | 438.78 Million | 514.58 Million | 503.54 Million |
| Earnings Per Share Basic | 1.15 | 0.78 | 0.74 | 0.97 | 1.14 | 1.11 |
| Earnings Per Share Diluted | 1.15 | 0.78 | 0.74 | 0.97 | 1.14 | 1.11 |
| Weighted Average Shares Outstanding | 453.33 Million | 451.33 Million | 449.83 Million | 452.35 Million | 453.35 Million | 453.35 Million |
| Weighted Average Shares Outstanding (Diluted) | 453.33 Million | 451.33 Million | 449.83 Million | 452.35 Million | 453.35 Million | 453.64 Million |
| Gross Margin | 0.57 | 0.56 | 0.55 | 0.57 | 0.57 | 0.57 |
| EBIT Margin | 0.19 | 0.16 | 0.16 | 0.18 | 0.18 | 0.21 |
| Profit Margin | 0.12 | 0.09 | 0.09 | 0.12 | 0.13 | 0.13 |
| EBITDA | 840.03 Million | 604.29 Million | 562.56 Million | 655.57 Million | 746.85 Million | 745.56 Million |
| Earnings Before Tax Margin | 0.13 | 0.09 | 0.09 | 0.13 | 0.14 | 0.15 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 931.72 Million | 910.18 Million | 1.14 Billion | 4.46 Billion | 1.25 Billion | 990.14 Million |
| Cost of Revenue | 410.37 Million | 473.79 Million | 434.45 Million | 1.83 Billion | 460.33 Million | 388.42 Million |
| Gross Profit | 521.35 Million | 436.39 Million | 714.49 Million | 2.62 Billion | 792.15 Million | 601.72 Million |
| Operating Expenses | 406.42 Million | 370.52 Million | 510.91 Million | 2.01 Billion | 584 Million | 475.06 Million |
| Selling, General and Administrative Expenses | 426.28 Million | 295.61 Million | 416.76 Million | - | 281.28 Million | 457.39 Million |
| Research and Development Expenses | 93.21 Million | 67.45 Million | 100.07 Million | - | 119.46 Million | 100.02 Million |
| Other Expenses | -113.07 Million | -7.45 Million | 1.21 Million | 3.27 Million | 2.58 Million | 403.81 Thousand |
| Cost and Expenses | 816.8 Million | 844.31 Million | 945.36 Million | 3.85 Billion | 1.04 Billion | 863.49 Million |
| Operating Income | 145.69 Million | 65.87 Million | 182.47 Million | 592.57 Million | 171.16 Million | 130.98 Million |
| Interest Expense | 2.99 Million | 1.34 Million | 1.34 Million | 6.58 Million | 1.65 Million | 1.88 Million |
| Income Tax Expense | 17.24 Million | -3.16 Million | 21.51 Million | 70.43 Million | 43.9 Million | 2.68 Million |
| Earnings before Tax | 146.87 Million | 108.36 Million | 183.69 Million | 595.85 Million | 173.74 Million | 131.38 Million |
| Net Income | 127.8 Million | 107.45 Million | 162.86 Million | 521.33 Million | 130.89 Million | 126.29 Million |
| Earnings Per Share Basic | 0.28 | 0.24 | 0.36 | - | 0.29 | 0.28 |
| Earnings Per Share Diluted | 0.28 | 0.24 | 0.36 | - | 0.29 | 0.28 |
| Weighted Average Shares Outstanding | 452.75 Million | 452.28 Million | 452.39 Million | 453.33 Million | 451.32 Million | 451.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 452.75 Million | 452.28 Million | 452.39 Million | 453.33 Million | 451.32 Million | 451.32 Million |
| Gross Margin | 0.56 | 0.48 | 0.62 | 0.59 | 0.63 | 0.61 |
| EBIT Margin | 0.16 | 0.14 | 0.20 | - | 0.19 | 0.15 |
| Profit Margin | 0.14 | 0.12 | 0.14 | 0.12 | 0.10 | 0.13 |
| EBITDA | 149.87 Million | 124.9 Million | 227.46 Million | - | 235.64 Million | 150.95 Million |
| Earnings Before Tax Margin | 0.16 | 0.07 | 0.16 | 0.13 | 0.14 | 0.13 |
JMT
NCI
AJB
SYNE3
000983
300845